...ma timeline, mesothelioma history, asbestos cancer history, CheckMate 743, FDA approval mesothelioma, mesothelioma research milestones
...t-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>
...
20 KB (2,490 words) - 20:57, 20 February 2026
..., researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvements.<ref name="ct-recrui
...18 months or longer with modern multimodal treatment approaches. The 2020 FDA approval of nivolumab plus ipilimumab marked the first new systemic therapy
...
38 KB (4,755 words) - 03:42, 9 March 2026
...thelioma immunotherapy, nivolumab ipilimumab, mesothelioma clinical trial, FDA approval 2020, Dr. Paul Baas, mesothelioma treatment
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approval
...
21 KB (2,642 words) - 09:18, 6 April 2026
...han doubled from 8.8 months to 18.1 months. These findings led directly to FDA approval in October 2020, transforming treatment options for mesothelioma p
...nd CheckMate 017, which helped establish checkpoint inhibitors as standard treatments for non-small cell lung cancer.
...
27 KB (3,530 words) - 04:00, 9 March 2026
= Mesothelioma Treatment Options and Costs: 4 FDA-Approved Therapies, $100,000-$400,000 Annual Expenses, and Financial Recovery Strate
...18.1-23 months compared to 12-14 months with chemotherapy alone. Four FDA-approved treatment pathways exist as of 2025: traditional chemotherapy, immunotherap
...
33 KB (3,904 words) - 20:57, 20 February 2026
* '''Immunotherapy:''' Opdivo (nivolumab) plus Yervoy (ipilimumab) FDA-approved 2020
* '''Tumor Treating Fields:''' Optune Lua device approved 2019
...
25 KB (3,138 words) - 20:56, 20 February 2026
...se, and cellular therapies demonstrating unprecedented durability. The FDA approved '''pembrolizumab plus chemotherapy''' in September 2024 as a new first-line
...esponse with pembrolizumab-chemo vs 29% with chemo alone''' — the 2024 FDA-approved combination nearly doubles confirmed response rates in first-line pleural m
...
39 KB (4,791 words) - 23:07, 10 March 2026
...e="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Regimens
...inine depletion therapy (BLA under FDA review), tumor treating fields (FDA-approved under Humanitarian Device Exemption), and mesothelin-targeted CAR-T cell th
...
55 KB (6,918 words) - 12:35, 6 April 2026
|title=TTFields / Optune Lua for Mesothelioma: STELLAR Trial, FDA Approval & Treatment Guide
...pleural mesothelioma. Covers STELLAR trial results (18.2-month median OS), FDA HDE approval, mechanism of action, treatment protocol, side effects, cost,
...
64 KB (8,231 words) - 09:57, 6 April 2026
...AR-T therapy has transformed the treatment of blood cancers — with six FDA-approved products achieving complete response rates as high as 90% in B-cell acute l
...e="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved for Meso
...
66 KB (8,673 words) - 02:53, 4 March 2026
The financial landscape shifted substantially in October 2020 when the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-li
* '''CAR-T therapy could exceed $500,000 per course''' — based on approved CAR-T pricing for other cancers, though mesothelioma-specific therapy remai
...
39 KB (4,954 words) - 23:00, 8 March 2026
...e="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approved
...therapy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus i
...
48 KB (5,851 words) - 22:11, 8 March 2026
...'Mesothelin Biomarker Accuracy''' || 61% sensitivity, 87% specificity; FDA-approved diagnostic marker<ref name="biomarkerdata" />
...Immunotherapy median OS 18.1 months vs. 14.1 months for chemotherapy; FDA approved October 2020<ref name="checkmate743" />
...
43 KB (5,354 words) - 03:51, 9 March 2026
...g:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved Treatments
...s vs. 16.1 months for chemo alone; 3-year OS 25% vs. 17%; ORR 52% vs. 29% (FDA approval September 2024)<ref name="keynote-483" />
...
59 KB (7,425 words) - 01:11, 6 April 2026
...e="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA-Approved
* ONCOS-102, an oncolytic adenovirus expressing GM-CSF, received FDA fast-track designation in 2021 after showing median overall survival of 20.
...
67 KB (8,763 words) - 09:18, 6 April 2026
...sothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>
...ion. Patients participating in clinical trials gain access to cutting-edge treatments unavailable through standard care while contributing to research that will
...
38 KB (4,540 words) - 01:11, 6 April 2026
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''FDA-Approved Systemic Regimens'''
...(measuring soluble mesothelin-related peptides/SMRP) remains the only FDA-approved blood biomarker, cleared in 2007 for monitoring treatment response — not sc
...
62 KB (7,831 words) - 01:11, 6 April 2026
...ps://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], MesotheliomaAttorney.com</ref>
The FDA-approved combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is available, alo
...
29 KB (3,526 words) - 20:56, 20 February 2026
...roves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Adm
* Immunotherapy combinations with conventional treatments
...
30 KB (3,613 words) - 20:56, 20 February 2026
...apidly through surrounding tissue, generally responding poorly to standard treatments and carrying the worst prognosis among mesothelioma subtypes.
...ng meaningful functional decline. ECOG 0-1 patients qualify for aggressive treatments including surgery and combination chemotherapy, while ECOG 2 patients may r
...
216 KB (26,444 words) - 23:30, 23 January 2026
